624 related articles for article (PubMed ID: 31538491)
1. PROTACs- a game-changing technology.
Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
[No Abstract] [Full Text] [Related]
2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
3. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.
Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW
J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
Si R; Hai P; Zheng Y; Liu N; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Med Chem Lett; 2023 May; 87():129275. PubMed ID: 37030566
[TBL] [Abstract][Full Text] [Related]
6. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes.
Zhang L; Riley-Gillis B; Vijay P; Shen Y
Mol Cancer Ther; 2019 Jul; 18(7):1302-1311. PubMed ID: 31064868
[TBL] [Abstract][Full Text] [Related]
7. Nano-PROTACs: state of the art and perspectives.
Zhong J; Zhao R; Wang Y; Su YX; Lan X
Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
[TBL] [Abstract][Full Text] [Related]
8. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
9. Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design.
Cecchini C; Tardy S; Scapozza L
Chimia (Aarau); 2022 Apr; 76(4):341-345. PubMed ID: 38069776
[TBL] [Abstract][Full Text] [Related]
10. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery.
Ermondi G; Garcia-Jimenez D; Caron G
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525371
[TBL] [Abstract][Full Text] [Related]
11. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C; Zhang Y; Chen W; Wu Y; Xing D
Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
[TBL] [Abstract][Full Text] [Related]
12. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).
Tomoshige S; Ishikawa M
Bioorg Med Chem; 2021 Jul; 41():116221. PubMed ID: 34034148
[TBL] [Abstract][Full Text] [Related]
13. Application of AlphaFold models in evaluating ligandable cysteines across E3 ligases.
Koldenhof P; Bemelmans MP; Ghosh B; Damm-Ganamet KL; van Vlijmen HWT; Pande V
Proteins; 2024 Jul; 92(7):819-829. PubMed ID: 38337153
[TBL] [Abstract][Full Text] [Related]
14. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.
Bricelj A; Steinebach C; Kuchta R; Gütschow M; Sosič I
Front Chem; 2021; 9():707317. PubMed ID: 34291038
[TBL] [Abstract][Full Text] [Related]
15. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
[TBL] [Abstract][Full Text] [Related]
16. Rational Prediction of PROTAC-Compatible Protein-Protein Interfaces by Molecular Docking.
Pereira GP; Jiménez-García B; Pellarin R; Launay G; Wu S; Martin J; Souza PCT
J Chem Inf Model; 2023 Nov; 63(21):6823-6833. PubMed ID: 37877240
[TBL] [Abstract][Full Text] [Related]
17. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
18. [Application of PROTACs in Hematological Malignancies--Review].
Jia YN; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
[TBL] [Abstract][Full Text] [Related]
19. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis-targeting chimeras with reduced off-targets.
Nguyen TM; Sreekanth V; Deb A; Kokkonda P; Tiwari PK; Donovan KA; Shoba V; Chaudhary SK; Mercer JAM; Lai S; Sadagopan A; Jan M; Fischer ES; Liu DR; Ebert BL; Choudhary A
Nat Chem; 2024 Feb; 16(2):218-228. PubMed ID: 38110475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]